Patients with long-standing, extensive ulcerative colitis (UC) Progression to Colorectal Neoplasia in Ulcerative Colitis: Effect of Mesalamine

Size: px
Start display at page:

Download "Patients with long-standing, extensive ulcerative colitis (UC) Progression to Colorectal Neoplasia in Ulcerative Colitis: Effect of Mesalamine"

Transcription

1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6: Progression to Colorectal Neoplasia in Ulcerative Colitis: Effect of Mesalamine THOMAS ULLMAN,* VICTORIA CROOG,* NOAM HARPAZ, SABERA HOSSAIN, ASHER KORNBLUTH,* CAROL BODIAN, and STEVEN ITZKOWITZ* *Dr. Henry D. Janowitz Division of Gastroenterology, Department of Medicine; Division of Gastrointestinal Pathology, Department of Pathology; and the Department of Biomathematical Sciences, Mount Sinai School of Medicine, New York, New York See CME exam on page Background & Aims: Some studies have suggested that mesalamine can prevent the development of colorectal cancer in patients with ulcerative colitis (UC). The aim of this study was to compare rates of progression with advanced neoplasia in patient cohorts with UC taking low and high doses of mesalamine and to determine where in the process of neoplastic progression mesalamine might act. Methods: Three cohorts of UC patients were identified from an institutional database: 311 patients with no dysplasia (NoD), 56 with indefinite dysplasia (IND), and 26 with flat low-grade dysplasia (flgd). The impact of mesalamine exposure on the subsequent development of advanced neoplasia (high-grade dysplasia or colorectal cancer) was assessed using life-table methods. Results: Seventeen of 311 patients with NoD progressed to advanced neoplasia (5-year rate, 1.1%). This rate was lower than the 5-year rate for the IND (9%; P.02 vs NoD) and flgd (45%; P <.001 vs NoD and P.001 vs IND) cohorts. Among the NoD cohort, the hazard ratio for mesalamine users versus nonusers was 0.70 (95% confidence interval, ), and for each 1 g/d increase in dose, the hazard ratio was 0.92 (95% confidence interval, ). For patients with IND, no patients on greater than 2 g/d progressed versus 13.8% on low-dose mesalamine (P.11). For flgd, 62.5% on high dose progressed, versus 27.8% on low dose (P.054). Conclusions: In long-standing UC, patients with flgd have a higher rate of progression to advanced neoplasia than those with NoD or IND. However, at none of these stages of disease did mesalamine use show definitive chemopreventive activity. Patients with long-standing, extensive ulcerative colitis (UC) carry an increased risk for the development of colorectal cancer (CRC). 1 It is commonly believed that the development of neoplasia in UC is manifested by progressively severe histologic abnormalities classified as low-grade dysplasia (LGD), highgrade dysplasia (HGD), and, ultimately, invasive carcinoma. 1 Despite attempts to prevent CRC by a program of periodic colonoscopic surveillance, and because the precancerous changes do not necessarily progress in a sequential manner, CRC still may occur without the prior discovery of dysplasia. 1 This raises the question of whether other approaches such as chemoprevention should be used in conjunction with surveillance colonoscopy. Several studies have examined whether mesalamine is chemopreventive in UC. 1 9 Its effect within a surveillance cohort and on progression from early to more advanced neoplasia are unknown, as is its relative influence at different points in the colitis-dysplasia-carcinoma sequence. Because most previous studies used a case-control design, little is known about the possible impact of mesalamine dose changes over time. In the present study, we attempted to address these issues by using a retrospective cohort design. This design allowed us to analyze changes in mesalamine dose over time as well as at different points in the colitis-dysplasia-carcinoma sequence. Ultimately, we analyzed 3 cohorts of patients representing different stages of early neoplastic progression for the development of higher grades of dysplasia or CRC. Materials and Methods Identification of Subjects This study was conducted with the approval of the Mount Sinai School of Medicine Institutional Review Board, and in accordance with the Health Insurance Portability and Accountability Act regulations. All patients were identified using the Mount Sinai Gastrointestinal Pathology database. Patients with no dysplasia (NoD) and indefinite dysplasia (IND) were drawn from a query of UC surveillance colonoscopies performed on UC patients from January 1996 through December This time period was chosen to allow for sufficient follow-up evaluation. The cohort of UC patients with flat LGD (flgd) originally was identified as part of a previous institutional review board approved study conducted by our group in which we queried the Pathology database from January 1994 through December Clinical Information By using the medical records of patients who were identified via the Gastrointestinal Pathology database query, a UC Surveillance Database was populated abstracting the following information: sex, date of birth, date of UC diagnosis Abbreviations used in this paper: CRC, colorectal cancer; flgd, flat low-grade dysplasia; HGD, high-grade dysplasia; IND, flat indefinite for dysplasia; LGD, low-grade dysplasia; NoD, no dysplasia; UC, ulcerative colitis by the AGA Institute /08/$34.00 doi: /j.cgh

2 1226 ULLMAN ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 6, No. 11 (based on the earlier of either symptom onset or diagnosis), and anatomic extent of disease. Extraintestinal manifestations and medication use were recorded. Pathology reports for all colonoscopies were reviewed, and, from these, the anatomic extent of inflammation and the location and number of all biopsies were tabulated. Endoscopy reports were reviewed and correlated with all pathology reports. Surgical reports and findings at colectomy both by the surgeon and the attending pathologist also were recorded. Other Inclusion and Exclusion Criteria Patients were included for a confirmed diagnosis of UC, and all colonoscopic examinations were considered to be for surveillance purposes if they were stated as such in the colonoscopy report, the pathology report, or if no specific reason for the examination was given and multiple biopsy specimens were taken in a patient with 7 or more years of disease. Patients were excluded if they had any previous colonic resection in an area of colitis, a diagnosis of Crohn s disease, a finding of IND or flgd outside of an area of colitis, a lack of endoscopic or surgical follow-up evaluation subsequent to inclusion, inadequate or absent information on mesalamine use, or inaccessible medical records. All clinical, endoscopic, and histologic diagnoses were recorded exactly as they were rendered in clinical practice; none were revised for the purpose of this study. In accordance with the retrospective nature of this study and consistent with the realities of routine clinical practice, the pathologist was unblinded to the patient s diagnosis, but was not made aware of any specifics of mesalamine use. Mesalamine Use The daily gram-equivalency of mesalamine was calculated as follows: one gram of sulfasalazine was considered equal to 0.4 g of mesalamine, one gram of balsalazide (Colazal; Salix Pharmaceuticals, Morrisville, NC) was equivalent to g of mesalamine, mesalamine (Asacol; Proctor and Gamble Pharmaceuticals, Cincinnati, OH and Pentasa; Shire Pharmaceuticals, Wayne, PA) and olsalazine (Dipentum; Alaven Pharmaceutical, LLC, Marietta, GA) had one-to-one equivalency. For the purpose of this study, a dose of greater than 2.0 g/d was considered high dose, whereas an average daily dose of 2.0 g or less, including those patients who never took mesalamine, was designated low dose. Histologic Interpretation All biopsy specimens were classified as NoD, IND, LGD, HGD, or invasive cancer (CRC) based on the criteria of the Inflammatory Bowel Disease Morphology Study Group. 11 The diagnoses were rendered prospectively by expert faculty members of Mount Sinai s Division of Gastrointestinal Pathology and confirmed in intradepartmental conference by its director, a gastrointestinal pathologist highly experienced in evaluating inflammatory bowel disease associated dysplasia (N.H.). Diagnoses were not altered and specimens were not re-evaluated as part of this study, but rather reflected the real-time status of patients as understood by their gastroenterologists as part of routine practice. Subclassifications of IND were not used in this study. Biopsy specimens with LGD were subclassified as flgd when the respective histologic diagnosis was made in the absence of concomitant documentation of a mass or polypoid lesion at that biopsy site by the endoscopist in either the endoscopy note or on the pathology request form. Patients were entered into the study at the first colonoscopy that showed NoD, IND, or flgd. Patients were considered to have NoD if they had no documentation of concomitant or previous polypoid or flat dysplasia or CRC; IND if they had no documentation of concomitant or previous IND, polypoid or flat dysplasia, or CRC; and flgd if they had no documentation of concomitant or previous polypoid LGD, or polypoid or flat HGD or CRC. Study Definitions Advanced neoplasia was defined as HGD or CRC. Progression was defined as the development of advanced neoplasia either during surveillance or at colectomy. Time zero was defined as the date of the initial surveillance colonoscopy that found NoD, IND, or flgd. Patients were censored at the time of their last colonoscopy without progression or until colectomy. The follow-up period was the time from time zero to progression or censoring. Statistical Analysis Medians and ranges were calculated for continuous variables; proportions were calculate for binary variables. The outcome of interest was progression to advanced neoplasia. Crude proportions are shown for descriptive purposes only. Life-table analysis was used to describe the progression and to test for the influence of covariates known at entry, such as duration of disease, extent of disease, primary sclerosing cholangitis, and age at onset of disease. The influence of the primary variable of interest, mesalamine use, was not always constant during the follow-up period. To account for this variable s changing status during the follow-up Figure 1. At time zero (t 0 ) all patients begin. Every time a patient in the cohort develops advanced neoplasia, an event is registered by the model, and the mean daily dose of mesalamine is calculated for each patient in the model from t 0 to the time of the event. Here, patient A develops HGD, and event A is registered. Each patient s mean daily dose of mesalamine is calculated from t 0 to the time of event A. The next event in the cohort is the development of colon cancer in patient B. The mean daily dose of mesalamine is calculated for each patient still under surveillance from t 0 to the time of event B. This is performed for events in the model, and the variable in question, in this case mesalamine dose, is assessed for its impact.

3 November 2008 MESALAMINE AND COLORECTAL NEOPLASIA IN UC 1227 Table 1. Patient Characteristics Mesalamine status NoD a (n 311) IND (n 56) flgd (n 26) High dose Low dose High dose Low dose High dose Low dose n(%) 93 (30) 218 (70) 27 (48) 29 (52) 8 (31) 18 (69) No mesalamine exposure, % Male, % Median age at UC diagnosis (range), y 27 (6 59) 27 (6 69) 25 (7 60) 24 (11 54) 26 (7 59) 28 (13 54) Median duration of UC at t 0 (range), y 13 (7 37) 16 (8 48) 17 (10 57) 17 (10 33) 16 (10 60) 22 (9 45) Extensive disease, % Primary sclerosing cholangitis, n (%) 0 (0) 3 (1) 1 (4) 5 (17) 0 (0) 0 (0) t 0, initial colonoscopy on record. a Mean taken over the course of each patient s surveillance history. The effect of the mesalamine dose was calculated as a time-changing covariate in this cohort, for which status above and below the 2 g/d equivalent could change during the follow-up period. period and to allow for assessment of its cumulative effect, it was analyzed as a time-changing covariate in a proportional hazards model (Cox regression) in the NoD cohort, 12 with values updated as follow-up evaluation proceeded (Figure 1). We have used this approach to study the effect of purine analog immunomodulator use on the progression to CRC in UC. 13 With the exception of the handling of mesalamine exposure as a time-changing covariate, there are no differences between this type of proportional hazards modeling and any other that examines the influence of independent variables on a timedependent outcome. In separate analyses, mesalamine use was characterized first by comparing those who ever used these medications with nonusers. Second, a cut-off level of 2 gramsequivalent per day mean exposure was assessed to evaluate for a greater than 0 threshold effect. Finally, dose effect over time was assessed by considering the cumulative average dose of mesalamine as a continuous variable. It turned out that no patients in the flgd cohort varied their dose across the 2 g/d threshold, and so analysis of this group was analyzed by comparing low- and high-dose users with mesalamine as a fixed, and not time-changing, covariate. In the IND cohort, this convention was used as well because only 2 patients crossed the 2 g/d threshold during the follow-up period. In addition to assessing the effect of mesalamine on progression in the 3 cohorts (NoD, IND, and flgd), we assessed the difference in rates of progression between the 3 cohorts themselves, using life-table analysis and log-rank testing. All analyses were performed using statistical software on a PC (SAS [SAS, Cary, NC] for NoD cohort analyses and SPSS [SPSS, Inc, Chicago, IL] for flgd and IND cohorts, as well as the analysis of progression between cohorts). Results Cohort Identification and Patient Characteristics From the UC Surveillance Database, 311 subjects met inclusion criteria for the NoD cohort, 56 for the IND cohort, and 26 for the flgd cohort. Fifty-nine patients were excluded because of incomplete information concerning mesalamine exposure. The clinical features of the subjects at the time of entry into the study are detailed in Table 1, and are classified according to patients mean daily dose of mesalamine averaged over the duration of their follow-up period. Between the cohorts, there were no significant differences in sex, age, and extent or duration of disease. There were, however, more patients with primary sclerosing cholangitis in the IND cohort on low-dose mesalamine (5 of 27; 17%) than high-dose mesalamine (1 of 29; 4%). Features of Patient Follow-Up Table 2 details the characteristics of surveillance among the 3 cohorts. The median time from entry into the study to the primary end point (advanced neoplasia or censoring at last colonoscopy without progression or surgery without progression) was nearly 7 years for the dysplasia-free group (initial NoD), but slightly less than half as long (3 years) for the groups with initial IND or flgd. Within each cohort, there were no important Table 2. Details of Patient Follow-Up Evaluation According to Dysplasia Status at Entry Into Study Mesalamine status NoD a (n 311) IND (n 56) flgd (n 26) High dose Low dose High dose Low dose High dose Low dose Follow-up duration, y 5.6 ( ) 7.4 ( ) 2.4 ( ) 4.1 ( ) 2.6 ( ) 3.0 ( ) Colonoscopies 5 (2 13) 5 (2 15) 3 (2 8) 5 (2 12) 4.5 (1 10) 4.5 (1 15) Surveillance interval, mo 17 (11 63) 20 (4 68) 12 (3 32) 13.1 (2 52) 13 (6 17) 9 (2 24) Specimen jars per colonoscopy 9 (3 12) 9 (4 12) 9 (7 14) 9 (7 11) 8 (5 11) 10 (7 15) Biopsy specimens per colonoscopy 14 (6 21) 13 (5 30) 16 (11 25) 14 (10 36) 18 (11 23) 16 (10 25) NOTE. All results are reported as median (range). t 0, initial colonoscopy on record. a The mean dose taken over the course of each patient s surveillance period. The effect of the mesalamine dose was calculated as a time-changing covariate in this cohort, for which status above and below the 2 g/d equivalent could change during the follow-up period.

4 1228 ULLMAN ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 6, No. 11 Table 3. Progression to Advanced Neoplasia in 3 Cohorts NoD (n 311) IND (n 56) flgd (n 26) Progressors, n Cases of CRC, n year rate of progression to advanced neoplasia (95% confidence interval) 1.1% (0% 2.3%) 9.0% (0% 19.2%) 44.9% (20.4% 69.4%) Low-dose mesalamine progressors, n 14/218 a 4/29 b 5/18 c High-dose mesalamine progressors, n 3/93 0/27 5/8 a See Table 4 for actuarial comparison of mesalamine use on progression to advanced neoplasia in the NoD cohort. b See Figure 3 for actuarial comparison of low- and high-dose mesalamine users. c See Figure 4 for actuarial comparison of low- and high-dose mesalamine users. differences in surveillance intensity between high-dose and lowdose groups. All patients had an average of 5 surveillance examinations during the follow-up period, which ranged from a median of 4.5 for the flgd cohort to 5 for the NoD cohort. The median time interval between surveillance examinations was longer for the NoD cohort (20 months) compared with the flgd cohort (12 months). Surveillance biopsy specimens were taken from a median of 8 to 10 sites throughout the colon, and the median number of biopsy specimens available for pathologic review ranged from 13 to 18 per examination. We first analyzed the overall rates of progression for each cohort (Table 3). Of the 311 patients in the NoD cohort, 17 progressed to advanced neoplasia; of these, 7 were CRCs. For the IND cohort, 4 of 56 subjects progressed (2 to CRC); 10 of the 26 flgd subjects progressed (3 to CRC). On an actuarial basis, the 5-year rate of progression to advanced neoplasia was 1%, 9%, and 45% for the NoD, IND, and flgd cohorts, respectively (Table 3, Figure 2). These rates were significantly different from each other: flgd showed a greater rate of progression compared with either the IND (P.001 by log-rank testing) or the NoD cohort (P.001 by log-rank testing); IND progressed at a greater rate than NoD (P.02 by log-rank testing). Of note, progression from NoD to advanced neoplasia did not appear linear; most events occurred 10 years after their first recorded surveillance examination. Progression in the IND and flgd cohorts occurred earlier (Figure 2). Effect of Mesalamine on Progression Dysplasia-free cohort. A proportional hazards analysis was performed on the NoD cohort coding mesalamine as a time-changing covariate and assessing its impact in 3 ways: (1) comparing those with mesalamine use at any time during surveillance with nonusers; (2) comparing those whose average dose was greater than 2 g/d with those with 2 g/d or less (with the mean dose calculated at each event as depicted in Figure 1); and (3) calculating the overall effect of mesalamine use for each 1-g increase in dose over the course of surveillance. By using this model, no statistically significant chemopreventive effect was shown comparing never users with any use of mesalamine, as well as comparing low- and high-dose users at the 2 g/d cut-off level (Table 4). In addition, for each 1-g increase in average daily mesalamine use, there was an 8% reduction in the hazard ratio estimate in our third analysis of this cohort; this estimate in reduction was not statistically significant. To determine whether known potential confounders altered the estimate of the effect of mesalamine use on subsequent neoplastic progression, we performed univariate assessment of these variables in a proportional hazards model, followed by multivariable testing for those variables whose P values were less than.10 (Cox regression). None of the potential confounders (sex, extent of disease, duration of disease, or age of onset) had a meaningful effect in univariate testing (data not shown; supplementary Table 1; see supplementary material online at testing was not performed on the primary sclerosing cholangitis group because so few patients in the NoD group had this diagnosis. In addition, none of these variables substantially modified the effect of mesalamine in multivariable analysis (data not shown). Indefinite dysplasia and low-grade dysplasia cohorts. Rates of progression to advanced neoplasia then were analyzed for the IND and LGD cohorts taking into account the Table 4. Effect of Mesalamine Use on Progression to Advanced Neoplasia in Proportional Hazards Model (Univariate) in Patients in NoD Cohort Any vs none Mesalamine use 2 vs 2 g/d For each 1-g/d increase in mesalamine vs none Figure 2. Progression to advanced neoplasia among patients in all cohorts. Hazard ratio % CI CI, confidence interval.

5 November 2008 MESALAMINE AND COLORECTAL NEOPLASIA IN UC 1229 Figure 3. Progression to advanced neoplasia in the IND cohort. mean daily dose of mesalamine over the entirety of each individual s surveillance history, and coded in a binary fashion with 2 g/d equivalent again serving as the cut-off value (Table 3, Figures 3 and 4). Overall, 14 patients with IND progressed to LGD, HGD, or CRC during follow-up evaluation. Of note, in the IND cohort, none of the 27 patients in the high-dose group progressed to HGD or CRC, whereas 4 of the 29 subjects in the low-dose group did. Despite this rather marked difference actuarially (Figure 3), statistical significance was not achieved (P.11 by log-rank test). For the LGD cohort, 5 patients in both the high- and low-dose groups progressed over the course of surveillance (Table 3, Figure 4). Patients on high-dose mesalamine seemed to progress more rapidly, although the actuarial difference in progression rates was not statistically significant (P.054 by log-rank test). Discussion Previous studies have found evidence both to support 2,3,5 8 and refute 4,9,14,15 mesalamine-based agents as chemopreventive in colitis-associated neoplasia. The present cohort study enabled us to address not only whether, but where, in the colitisdysplasia-carcinoma sequence mesalamine compounds might exert a chemopreventive effect. Our methodology also allowed us to account for changes in mesalamine exposure over time, an underappreciated concept in the chemopreventive literature, in which some studies have defined exposure as just 3 months of continuous use at any time during the course of UC. We did not detect a significant chemopreventive effect for mesalamine, although point estimates slightly favored chemoprevention in the NoD and IND groups. In the NoD group, a mean daily dose of at least 2gof mesalamine resulted in a hazard ratio estimate of 0.77, but the upper boundary of the 95% confidence interval was greater than 1. Likewise, in the IND group, there were no progression events in the high-dose mesalamine group, whereas nearly 14% of patients in the low-dose group went on to develop advanced neoplasia. Overall, therefore, no chemopreventive effect was found, although the possibility of a weak effect remains. One possible reason why we were unable to achieve statistical significance using the proportional hazards model is that there were very few progression events in the NoD group. Before undertaking our study, little information was available regarding rates of progression among individuals with dysplasia-free screening examinations. By simultaneously performing an analysis of the natural history of neoplastic progression within each cohort, we found strikingly different 5-year actuarial rates of progression to advanced neoplasia between patients with initial NoD (1%), IND (9%), and flgd (45%). Because event rates drive the sample size calculations, we calculate that given the hazard ratio observed, we would have needed approximately 3000 patients with an initial surveillance finding of NoD to reach statistical significance. Another corollary to the low event rate stems from the probability that dysplasia surveillance works by identifying those at greatest risk at the initial (screening) examination. Our observed event rate for the NoD cohort is less than half of what would have been expected based on the Eaden et al 7 meta-analysis, and suggests that the so-called natural history of patients in a surveillance program is different from the natural history of UC patients overall. Recent evidence from a case-control study supports the concept that exposure to colonoscopy reduces the risk of CRC in longstanding colitis independent of exposure to anti-inflammatory medications. 16 It is quite possible, therefore, that the absolute risk reduction of mesalamine (or any putative chemopreventive agent) is small in the context of a surveillance program in which an initial examination decreases the hazard for those who are dysplasia-free by greater than half. The flgd group showed a fairly high rate of progression to advanced neoplasia, regardless of mesalamine dose. Although the flgd cohort was created in a similar fashion to the IND and NoD cohorts, the calendar time band of inclusion was somewhat greater, with 8 of the 26 flgd patients having all of their examinations before or after , the requirement for inclusion in the IND or NoD cohorts. It is doubtful, however, that this subtle difference introduced any selection biases because neither the indications for colectomy nor the histologic interpretation of dysplasia by our expert gastrointestinal pathologists changed during these time periods. Curiously, high-dose mesalamine use after flgd appeared to increase the risk of progression in this small cohort. This lack of chemopreventive activity for mesalamine in the flgd group is not surprising because we previously reported a substantial risk of synchronous or metachronous advanced neoplasia once flgd was found. 10 It is noteworthy that the actuarial progression of IND patients in our study was intermediate between the NoD and LGD groups. Figure 4. Progression to advanced neoplasia in the flgd cohort.

6 1230 ULLMAN ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 6, No. 11 Our findings suggest that despite the heterogeneity and inherent uncertainty of this category, patients diagnosed with IND may represent a subgroup that might be useful in future chemoprevention studies. Little is known about the natural history of IND, and some have questioned whether this histologic category is clinically meaningful. Our results showed that a finding of IND at surveillance carries a risk intermediate to that of flgd and NoD. A potential limitation of our study was that we created and analyzed results from a single-center, nonprotocolized, retrospective, surveillance system database. Although the single-center orientation of the study raises some concerns about the external validity of our findings, it is hard to imagine that mesalamine exposure somehow exerted a different effect at our center than would have been seen in subjects at another center, in a multi-institutional study, or in a population-based cohort. Another potential limitation to the validity of our findings was a result of our nonprotocolized surveillance system. This might have resulted in less regimented surveillance intervals or insufficient biopsy sampling than would be seen in a protocol-based system. Although these features could have affected our findings, we found that surveillance frequency and biopsy practices were similar between low-dose and high-dose mesalamine users. Actually, varied surveillance may improve the external validity of our results because most clinicians in practice perform dysplasia surveillance outside the confines of a clinical trial, and are free to perform examinations at varied intervals with varied biopsy practices. Also, the fact that all slides were interpreted by a single group of gastrointestinal pathologists and reviewed by one expert may explain why we were able to discern distinct natural history curves for the NoD, IND, and LGD groups. Although this single-group:one-expert paradigm may limit the generalizability of our findings, there is no accepted manner to broker disagreements between old reports and updated reinterpretations; we therefore elected not to have specimens re-read. Of note, pathologists were blind to mesalamine doses. As for the retrospective nature of our study, we doubt that this orientation biased our results because much of the data collected antedated the first positive studies for mesalamine as a chemopreventive agent, and no meaningful changes in prescribing habits were observed after these publications. It is doubtful that our colleagues were sufficiently prescient to have altered their mesalamine prescribing habits in advance of these initial works. In conclusion, our findings failed to show chemoprevention for mesalamines in colitis-related CRC for patients enrolled in a surveillance program. Although there still remains the possibility that mesalamine compounds play a chemopreventive role for CRC in UC, a rather large cohort would be needed to show such an effect in a statistically significant way. Further studies are required to elucidate the role of chemopreventive agents in UC patients under surveillance. Supplementary Data Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at References 1. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004;126: van Staa TP, Card T, Logan RF, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005;54: Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100: Bernstein CN, Blanchard JF, Metge C, et al. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003;98: Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8: Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994;107: Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14: Rubin DT, LoSavio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 2006;4: Terdiman JP, Steinbuch M, Blumentals WA, et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 2007;13: Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003;125: Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14: Cox DR. Regression models and life tables. J R Stat Soc Ser B Method 1972;34: Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005;3: Lashner BA, Heidenreich PA, Su GL, et al. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology 1989; 97: Lashner BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112: Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006;130: Address requests for reprints to: Thomas A. Ullman, MD, Gastrointestinal Division, Box 1069, Mount Sinai School of Medicine, One Gustave Levy Place, New York, New York thomas. ullman@msnyuhealth.org; fax: (212) Supported by grants from Procter and Gamble Pharmaceuticals, The American College of Gastroenterology, and the National Institutes of Health (K-08-DK069393). In addition to sponsorship, speakers bureau support was received from Procter and Gamble (T.U., A.K., S.I.), Shire Pharmaceuticals (T.U., A.K.), and Salix Pharmaceuticals (A.K.), and T.U., A.K., S.I. were consultants for Procter and Gamble, and T.U. was a consultant for Shire Pharmaceuticals. The authors would like to acknowledge and thank the many faculty members of the Dr. Henry D. Janowitz Division of Gastroenterology who shared their charts and wisdom with us, and without whom this effort would not have been possible.

Chemoprevention of Colorectal Neoplasia in Ulcerative Colitis: The Effect of 6-Mercaptopurine

Chemoprevention of Colorectal Neoplasia in Ulcerative Colitis: The Effect of 6-Mercaptopurine CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1015 1021 Chemoprevention of Colorectal Neoplasia in Ulcerative Colitis: The Effect of 6-Mercaptopurine SIERRA MATULA,* VICTORIA CROOG,* STEVEN ITZKOWITZ,*

More information

There is a well-established association between inflammatory

There is a well-established association between inflammatory CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1346 1350 Aminosalicylate Therapy in the Prevention of Dysplasia and Colorectal Cancer in Ulcerative Colitis DAVID T. RUBIN, ANDELKA LOSAVIO, NICOLE YADRON,

More information

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center

More information

Patients with longstanding ulcerative colitis (UC) or

Patients with longstanding ulcerative colitis (UC) or ORIGINAL ARTICLE Misclassification of Dysplasia in Patients with Inflammatory Bowel Disease: Consequences for Progression Rates to Advanced Neoplasia Fiona D.M. van Schaik, MD,* Fiebo J.W. ten Kate, MD,

More information

C olorectal cancer (CRC) is one of the most feared

C olorectal cancer (CRC) is one of the most feared 1573 INFLAMMATORY BOWEL DISEASE 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study T P van Staa, T Card, R F Logan, H G M Leufkens... See end

More information

CRC and Dysplasia in IBD: Objectives of Talk. Colorectal Cancer and Dysplasia in IBD: A Case-Based Approach. Page 1

CRC and Dysplasia in IBD: Objectives of Talk. Colorectal Cancer and Dysplasia in IBD: A Case-Based Approach. Page 1 Colorectal Cancer and in IBD: A Case-Based Approach Fernando Velayos MD MPH Associate Director of Translational Research University of California, San Francisco Center for Crohn s s and Colitis CRC and

More information

Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts

Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management

More information

Advances in Ulcerative Colitis - Volume 3 CME

Advances in Ulcerative Colitis - Volume 3 CME 1 de 12 22/01/2008 04:46 p.m. More: Advances in Ulcerative Colitis Advances in Ulcerative Colitis - Volume 3 CME Complete author affiliations and disclosures are at the end of this activity. Release Date:

More information

CASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD

CASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD CASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD Disclosure Statement NKC: No relevant conflicts to disclose. DTR: No relevant

More information

Dysplasia 4/19/2017. How do I practice Chromoendoscopy for Surveillance of Colitis? SCENIC: Polypoid Dysplasia in UC. Background

Dysplasia 4/19/2017. How do I practice Chromoendoscopy for Surveillance of Colitis? SCENIC: Polypoid Dysplasia in UC. Background SCENIC: Polypoid in UC Definition How do I practice for Surveillance of Colitis? Themos Dassopoulos, M.D. Director, BSW Center for IBD Themistocles.Dassopoulos@BSWHealth.org Tel: 469-800-7189 Cell: 314-686-2623

More information

Chromoendoscopy or Narrow Band Imaging with Targeted biopsies Should be the Cancer Surveillance Endoscopy Procedure of Choice in Ulcerative Colitis

Chromoendoscopy or Narrow Band Imaging with Targeted biopsies Should be the Cancer Surveillance Endoscopy Procedure of Choice in Ulcerative Colitis Chromoendoscopy or Narrow Band Imaging with Targeted biopsies Should be the Cancer Surveillance Endoscopy Procedure of Choice in Ulcerative Colitis Bret A. Lashner, M.D. Professor of Medicine Director,

More information

Diagnostic techniques for surveillance of dysplasia

Diagnostic techniques for surveillance of dysplasia January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Diagnostic techniques for surveillance of dysplasia Gerhard Rogler, Department of Gastroenterology

More information

White Rose Research Online URL for this paper: Version: Accepted Version

White Rose Research Online URL for this paper:   Version: Accepted Version This is a repository copy of Patients with Endoscopically Visible Polypoid Adenomatous Lesions Within the Extent of Ulcerative Colitis Have an Increased Risk of Colorectal Cancer Despite Endoscopic Resection.

More information

IBD high risk groups

IBD high risk groups IBD high risk groups Ulcerative colitis Value (95% CI) CRC prevalence (%) 3.7 (3.2-4.2) Overall annual CRC incidence (%) 0.3 (0.2-0.4) Annual CRC incidence in first decade of UC (%) 0.2 (0.1-0.2) Annual

More information

Diagnosis and Management of Flat and Polypoid Dysplasia in Inflammatory Bowel Disease

Diagnosis and Management of Flat and Polypoid Dysplasia in Inflammatory Bowel Disease Diagnosis and Management of Flat and Polypoid Dysplasia in Inflammatory Bowel Disease Francis A. Farraye, MD, MSc Clinical Director, Section of Gastroenterology, Boston Medical Center Professor of Medicine,

More information

Int J Clin Exp Med 2015;8(2): /ISSN: /IJCEM

Int J Clin Exp Med 2015;8(2): /ISSN: /IJCEM Int J Clin Exp Med 2015;8(2):2212-2218 www.ijcem.com /ISSN:1940-5901/IJCEM0003699 Original Article Chemopreventive effects of 5-amino salicylic acids on inflammatory bowel disease-associated colonic cancer

More information

Chromoendoscopy - Should It Be Standard of Care in IBD?

Chromoendoscopy - Should It Be Standard of Care in IBD? Chromoendoscopy - Should It Be Standard of Care in IBD? John F. Valentine, MD, FACG Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Utah What is the point of

More information

Colorectal Cancer in Inflammatory Bowel Disease

Colorectal Cancer in Inflammatory Bowel Disease Gut and Liver, Vol. 2, No. 2, September 2008, pp. 61-73 review Colorectal Cancer in Inflammatory Bowel Disease Jonathan Potack and Steven H. Itzkowitz Division of Gastroenterology, Department of Medicine,

More information

MINI-REVIEW. Should we Sound the Alarm? Dysplasia and Colitis-associated Colorectal Cancer. Lin-Lin Ren, Jing-Yuan Fang * Abstract.

MINI-REVIEW. Should we Sound the Alarm? Dysplasia and Colitis-associated Colorectal Cancer. Lin-Lin Ren, Jing-Yuan Fang * Abstract. Should we Sound the Alarm?- Dysplasia and Colitis-associated Colorectal Cancer MINI-REVIEW Should we Sound the Alarm? Dysplasia and Colitis-associated Colorectal Cancer Lin-Lin Ren, Jing-Yuan Fang * Abstract

More information

How to characterize dysplastic lesions in IBD?

How to characterize dysplastic lesions in IBD? How to characterize dysplastic lesions in IBD? Name: Institution: Helmut Neumann, MD, PhD, FASGE University Medical Center Mainz What do we know? Patients with IBD carry an increased risk of developing

More information

Prevalence of Nonadherence With Maintenance Mesalamine in Quiescent Ulcerative Colitis

Prevalence of Nonadherence With Maintenance Mesalamine in Quiescent Ulcerative Colitis THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 96, No. 10, 2001 2001 by Am. Coll. of Gastroenterology ISSN 0002-9270/01/$20.00 Published by Elsevier Science Inc. PII S0002-9270(01)03245-2 Prevalence of

More information

The variable risk of colorectal cancer in patients with inflammatory bowel disease.

The variable risk of colorectal cancer in patients with inflammatory bowel disease. The variable risk of colorectal cancer in patients with inflammatory bowel disease. Lindgren, Stefan Published in: European Journal of Internal Medicine DOI: 10.1016/j.ejim.2004.12.001 Published: 2005-01-01

More information

Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease

Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease Aliment Pharmacol Ther 23; 18 (Suppl. 2): 1 5. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease P. MUNKHOLM Department of Medical Gastroenterology, Hvidovre

More information

Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis

Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis Alimentary Pharmacology & Therapeutics Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis T. THOMAS*, K. A. ABRAMS, R.J.ROBINSON*&J.F.MAYBERRY* *Department of Gastroenterology,

More information

Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis

Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis Alimentary Pharmacology and Therapeutics Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis G. R. Lichtenstein*,

More information

Malignancy in ulcerative colitis (UC) is believed to ORIGINAL ARTICLES

Malignancy in ulcerative colitis (UC) is believed to ORIGINAL ARTICLES CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:534 541 ORIGINAL ARTICLES Long-term Follow-up After Polypectomy Treatment for Adenoma-Like Dysplastic Lesions in Ulcerative Colitis ROBERT D. ODZE,* FRANCIS

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators

More information

DIVISION OF GASTROENTEROLOGY

DIVISION OF GASTROENTEROLOGY DR. Lloyd Mayer T H E H E N R Y D. J A N O W I T Z DIVISION OF GASTROENTEROLOGY Mount Sinai is consistently ranked among the top five gastroenterology centers in the nation. The irresistible combination

More information

Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population

Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population David T. Rubin, M.D. Assistant Professor of Medicine Inflammatory Bowel Disease Center MacLean Center for Clinical Medical Ethics

More information

Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn s colitis patients in the Netherlands

Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn s colitis patients in the Netherlands Online Submissions: wjg.wjgnet.com World J Gastroenterol 9 January 14; 15(2): 226-23 wjg@wjgnet.com World Journal of Gastroenterology ISSN 17-9327 doi:1.3748/wjg.15.226 9 The WJG Press and Baishideng.

More information

New Approaches for Early Detection of Ulcerative Colitis (UC) Associated Cancer and Surgical Treatment of UC Patients

New Approaches for Early Detection of Ulcerative Colitis (UC) Associated Cancer and Surgical Treatment of UC Patients New Approaches for Early Detection of Ulcerative Colitis (UC) Associated Cancer and Surgical Treatment of UC Patients Toshiaki Watanabe, M.D., Ph.D. Department of Surgery, Teikyo University School of Medicine,

More information

Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA

Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA Endpoints Overview Hospitalization Surgery Colorectal cancer

More information

Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis

Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis Journal of Crohn's and Colitis (2013) 7, 974 981 Available online at www.sciencedirect.com ScienceDirect Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary

More information

IBD and Cancer: Myths and Facts

IBD and Cancer: Myths and Facts IBD and Cancer: Myths and Facts Thomas A. Ullman, MD Medical Director, Faculty Prac>ce Department of Medicine Icahn School of Medicine at Mount Sinai New York, USA Risk of Colorectal Cancer in UC Eaden

More information

Moderately to severely active ulcerative colitis

Moderately to severely active ulcerative colitis Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients

More information

Chromoendoscopy and Endomicroscopy for detecting colonic dysplasia

Chromoendoscopy and Endomicroscopy for detecting colonic dysplasia Chromoendoscopy and Endomicroscopy for detecting colonic dysplasia Ralf Kiesslich I. Medical Department Johannes Gutenberg University Mainz, Germany Cumulative cancer risk in ulcerative colitis 0.5-1.0%

More information

AGA Technical Review on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease

AGA Technical Review on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease GASTROENTEROLOGY 2010;138:746 774 AGA Technical Review on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease AGA Podcast interview: www.gastro.org/gastropodcast. Learning

More information

removal of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2

removal of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2 Supplementary Table 1. Study Characteristics Author, yr Design Winawer et al., 6 1993 National Polyp Study Jorgensen et al., 9 1995 Funen Adenoma Follow-up Study USA Multi-center, RCT for timing of surveillance

More information

Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn s disease and polyps

Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn s disease and polyps Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn s disease and polyps Full guideline Draft for consultation, May 00 0 This guideline

More information

When and How to use Chromoendoscopy in IBD

When and How to use Chromoendoscopy in IBD When and How to use Chromoendoscopy in IBD Samir A. Shah, MD, FACG, FASGE, AGAF Clinical Professor of Medicine, Brown University Chief of Gastroenterology, The Miriam Hospital Gastroenterology Associates,

More information

Chromoendoscopy as an Adjunct to Colonoscopy

Chromoendoscopy as an Adjunct to Colonoscopy Chromoendoscopy as an Adjunct to Colonoscopy Policy Number: 2.01.84 Last Review: 1/2018 Origination: 7/2017 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide

More information

NIH Public Access Author Manuscript Inflamm Bowel Dis. Author manuscript; available in PMC 2013 December 01.

NIH Public Access Author Manuscript Inflamm Bowel Dis. Author manuscript; available in PMC 2013 December 01. NIH Public Access Author Manuscript Published in final edited form as: Inflamm Bowel Dis. 2012 December ; 18(12): 2240 2246. doi:10.1002/ibd.22912. Prospective Study of the Progression of Low-Grade Dysplasia

More information

Safety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease

Safety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease Safety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease Vinna An, Ashwinna Asairinachan, Michael Johnston, James Keck, Paul Salama, Steven Brown, Rodney Woods Department of Colorectal

More information

Colorectal cancer surveillance in inflammatory bowel diseases

Colorectal cancer surveillance in inflammatory bowel diseases Turkish Journal of Cancer Volume 34, No.2, 2004 55 Colorectal cancer surveillance in inflammatory bowel diseases MURAT TÖRÜNER Ankara University Medical School, Department of Gastroenterology, Ankara-Turkey

More information

High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease

High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease Accepted Manuscript High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease Shailja C. Shah, Joren R. ten Hove, Daniel Castaneda,

More information

Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview

Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview 1022 ORIGINAL CONTRIBUTIONS nature publishing group see related editorial on page 1035 Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview

More information

Synopsis. Clinical Report Synopsis for Protocol Name of Company: Otsuka Pharmaceutical Development & Commercialization, Inc.

Synopsis. Clinical Report Synopsis for Protocol Name of Company: Otsuka Pharmaceutical Development & Commercialization, Inc. Synopsis Clinical Report Synopsis for Protocol 197-02-220 Name of Company: Otsuka Pharmaceutical Development & Commercialization, Inc. Name of Product: Tetomilast (OPC-6535) Study Title: A Phase 3, Multicenter,

More information

Risk for Colorectal Neoplasia in Patients With Colonic Crohn s Disease and Concomitant Primary Sclerosing Cholangitis

Risk for Colorectal Neoplasia in Patients With Colonic Crohn s Disease and Concomitant Primary Sclerosing Cholangitis CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:303 308 Risk for Colorectal Neoplasia in Patients With Colonic Crohn s Disease and Concomitant Primary Sclerosing Cholangitis BARBARA BRADEN,* JOHNNY HALLIDAY,*

More information

Low-Grade Dysplasia in Ulcerative Colitis: Risk Factors for Developing High-Grade Dysplasia or Colorectal Cancer

Low-Grade Dysplasia in Ulcerative Colitis: Risk Factors for Developing High-Grade Dysplasia or Colorectal Cancer nature publishing group ORIGINAL CONTRIBUTIONS 1461 CME see related editorial on page 1473 Low-Grade Dysplasia in Ulcerative Colitis: Risk Factors for Developing High-Grade Dysplasia or Colorectal Cancer

More information

Mucosal healing: does it really matter?

Mucosal healing: does it really matter? Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does

More information

Colonoscopy with polypectomy significantly reduces colorectal

Colonoscopy with polypectomy significantly reduces colorectal CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:562 567 Utilization and Yield of Surveillance Colonoscopy in the Continued Follow-Up Study of the Polyp Prevention Trial ADEYINKA O. LAIYEMO,*, PAUL F. PINSKY,

More information

Ulcerative colitis (UC) and Crohn s disease (CD) have

Ulcerative colitis (UC) and Crohn s disease (CD) have GASTROENTEROLOGY 2006;130:1039 1046 Risk of Intestinal Cancer in Inflammatory Bowel Disease: A Population-Based Study From Olmsted County, Minnesota TINE JESS,* EDWARD V. LOFTUS JR, FERNANDO S. VELAYOS,

More information

Ulcerative colitis (UC) is a chronic disease that is commonly

Ulcerative colitis (UC) is a chronic disease that is commonly ORIGINAL ARTICLE Voting with Their Feet (VWF) Endpoint: A Meta-Analysis of an Alternative Endpoint in Clinical Trials, Using 5-ASA Induction Studies in Ulcerative Colitis Sujal C. Rangwalla, DO,* Akbar

More information

Novel Optical Research at UPMC

Novel Optical Research at UPMC Novel Optical Research at UPMC Randall Brand, MD Professor of Medicine Division of Gastroenterology, Hepatology, & Nutrition University of Pittsburgh Medical Center Background Patients with UC and CD of

More information

Accepted Manuscript. En bloc resection for mm polyps to reduce post-colonoscopy cancer and surveillance. C. Hassan, M. Rutter, A.

Accepted Manuscript. En bloc resection for mm polyps to reduce post-colonoscopy cancer and surveillance. C. Hassan, M. Rutter, A. Accepted Manuscript En bloc resection for 10-20 mm polyps to reduce post-colonoscopy cancer and surveillance C. Hassan, M. Rutter, A. Repici PII: S1542-3565(19)30412-4 DOI: https://doi.org/10.1016/j.cgh.2019.04.022

More information

HLA TYPING AND EXPRESSION: POTENTIAL MARKER FOR IDENTIFYING EARLY DYSPLASIA AND STRATIFYING THE RISK FOR IBD-CANCER

HLA TYPING AND EXPRESSION: POTENTIAL MARKER FOR IDENTIFYING EARLY DYSPLASIA AND STRATIFYING THE RISK FOR IBD-CANCER HLA TYPING AND EXPRESSION: POTENTIAL MARKER FOR IDENTIFYING EARLY DYSPLASIA AND STRATIFYING THE RISK FOR IBD-CANCER Megan Garrity, S. Breanndan Moore, M.D., William Sandborn, M.D., Vernon Pankratz, Ph.D.,

More information

Quality in Endoscopy: Can We Do Better?

Quality in Endoscopy: Can We Do Better? Quality in Endoscopy: Can We Do Better? Erik Rahimi, MD Assistant Professor Division of Gastroenterology, Hepatology, and Nutrition UT Health Science Center at Houston McGovern Medical School Ertan Digestive

More information

Screening & Surveillance Guidelines

Screening & Surveillance Guidelines Chapter 2 Screening & Surveillance Guidelines I. Eligibility Coloradans ages 50 and older (average risk) or under 50 at elevated risk for colon cancer (personal or family history) that meet the following

More information

BENEFIT APPLICATION BLUE CARD/NATIONAL ACCOUNT ISSUES

BENEFIT APPLICATION BLUE CARD/NATIONAL ACCOUNT ISSUES Medical Policy BCBSA Ref. Policy: 2.01.84 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 2.01.87 Confocal Laser Endomicroscopy 6.01.32 Virtual Colonoscopy/Computed

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant

More information

Review Article Chronic Inflammation and Malignancy in Ulcerative Colitis

Review Article Chronic Inflammation and Malignancy in Ulcerative Colitis Ulcers Volume 2011, Article ID 714046, 8 pages doi:10.1155/2011/714046 Review Article Chronic Inflammation and Malignancy in Ulcerative Colitis Sai Sunkara, 1 Garth Swanson, 2 Christopher B. Forsyth, 2

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn

More information

Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study

Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 6- O Olén,,, J Askling, MC Sachs, P Frumento, M Neovius, KE Smedby, A Ekbom, P Malmborg,,5 JF Ludvigsson

More information

When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool

When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool Adenomas/Carcinoma Sequence Providing Time for Screening Normal 5-20 yrs 5-15 yrs

More information

Sialyl-Tn Antigen as a Marker of Colon Cancer Risk in Ulcerative Colitis: Relation to Dysplasia and DNA Aneuploidy

Sialyl-Tn Antigen as a Marker of Colon Cancer Risk in Ulcerative Colitis: Relation to Dysplasia and DNA Aneuploidy GASTROENTEROLOGY 1998;115:1395 1404 Sialyl-Tn Antigen as a Marker of Colon Cancer Risk in Ulcerative Colitis: Relation to Dysplasia and DNA Aneuploidy PER KARLÉN,* ERIC YOUNG, OLLE BROSTRÖM,* ROBERT LÖFBERG,

More information

Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer

Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer ORIGINAL ARTICLE pissn 1598-9100 eissn 2288-1956 http://dx.doi.org/10.5217/ir.2016.14.3.264 Intest Res 2016;14(3):264-269 Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients

More information

Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases

Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases Parakkal Deepak, M.B.B.S., M.S. Assistant Professor of Medicine Division of Gastroenterology John T. Milliken Department

More information

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty

More information

NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente

NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND Fabrizio Parente Gastrointestinal Unit, A.Manzoni Hospital, Lecco & L.Sacco School of Medicine,University of Milan - Italy

More information

High frequency of early colorectal cancer in inflammatory bowel disease

High frequency of early colorectal cancer in inflammatory bowel disease See Commentary, p 1194 1 Department of Hepatology, University Medical Center, Utrecht, The Netherlands; 2 Department of Pathology, University Medical Center, Utrecht, The Netherlands; 3 Department of Hepatology,

More information

Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines

Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines INVITED REVIEW Annals of Gastroenterology (2012) 25, 1-8 Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines Vicent Hernández a, Juan Clofent b Complexo Hospitalario

More information

Title: Serrated polyposis syndrome associated with long-standing inflammatory bowel disease

Title: Serrated polyposis syndrome associated with long-standing inflammatory bowel disease Title: Serrated polyposis syndrome associated with long-standing inflammatory bowel disease Authors: Jesús Castro, Miriam Cuatrecasas, Francesc Balaguer, Elena Ricart, María Pellisé DOI: 10.17235/reed.2017.5068/2017

More information

As clinicians we would all agree that the goal for our

As clinicians we would all agree that the goal for our CURRENT CONTROVERSIES: PRO, CON, AND BALANCE Controversies in Mucosal Healing in Ulcerative Colitis Sunanda Kane, MD,* Frances Lu, MD, Asher Kornbluth, MD, Dahlia Awais, MD, and Peter D.R. Higgins, MD,

More information

Management of pt1 polyps. Maria Pellise

Management of pt1 polyps. Maria Pellise Management of pt1 polyps Maria Pellise Early colorectal cancer Malignant polyp Screening programmes SM Invasive adenocar cinoma Advances in diagnostic & therapeutic endoscopy pt1 polyps 0.75 5.6% of large-bowel

More information

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage

More information

Inflammatory Bowel Disease: Clinical updates. Dr Jeff Chao Princess Alexandra Hospital

Inflammatory Bowel Disease: Clinical updates. Dr Jeff Chao Princess Alexandra Hospital Inflammatory Bowel Disease: Clinical updates Dr Jeff Chao Princess Alexandra Hospital Inflammatory bowel disease 2017 Clinical updates and future directions Pathogenesis Treatment targets Therapeutic agents

More information

EXPERT WORKING GROUP Surveillance after neoplasia removal. Meeting Chicago, May 5th 2017 Chair: Rodrigo Jover Uri Ladabaum

EXPERT WORKING GROUP Surveillance after neoplasia removal. Meeting Chicago, May 5th 2017 Chair: Rodrigo Jover Uri Ladabaum EXPERT WORKING GROUP Surveillance after neoplasia removal Meeting Chicago, May 5th 2017 Chair: Rodrigo Jover Uri Ladabaum AIM To improve the quality of the evidences we have regarding post- polypectomy

More information

Title Description Type / Priority

Title Description Type / Priority Merit-based Incentive Payment system (MIPS) 2019 Qualified Clinical Data Registry (QCDR) Measure Specifications Summary Listing of QCDR measures supported by the NHCR Measure # NHCR4 NHCR5 GIQIC12 GIQIC15

More information

Recurrence and survival rates of inflammatory bowel disease-associated colorectal cancer following postoperative chemotherapy: a comparative study

Recurrence and survival rates of inflammatory bowel disease-associated colorectal cancer following postoperative chemotherapy: a comparative study Gastroenterology Report, 5(1), 2017, 57 61 doi: 10.1093/gastro/gow016 Advance Access Publication Date: 8 June 2016 Original article ORIGINAL ARTICLE Recurrence and survival rates of inflammatory bowel

More information

DENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease

DENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

associated with severe symptoms and impaired quality of life. UC may affect all ages and medical treatment depends on disease severity and extent. In the case of intractable disease, colectomy may be indicated.

More information

East west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort

East west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort East west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort diseasespictures.com Balazs Radnai and Martin Eigler Statistik II. Course 27.01.2014. Introduction

More information

Objec-ve. Case Presenta-ons and Ques-ons to Panel. Dysplasia case 11/13/11

Objec-ve. Case Presenta-ons and Ques-ons to Panel. Dysplasia case 11/13/11 Case Presenta-ons and Ques-ons to Panel UCSF IBD Symposium November 12, 2011 Moderator Fernando Velayos MD Panelists Brian Feagan, MD James Lewis, MD MSCE Robert Cima, MD Hueylan Chern, MD Sunanda Kane,

More information

POST TRANSPLANT OUTCOMES IN PSC

POST TRANSPLANT OUTCOMES IN PSC POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners

More information

Comparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn s disease

Comparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn s disease Gastroenterology Report, 4(1), 2016, 43 49 doi: 10.1093/gastro/gou074 Advance Access Publication Date: 29 October 2014 Original article ORIGINAL ARTICLE Comparison of outcomes for patients with primary

More information

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions

More information

Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation

Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation ORIGINAL ARTICLE Annals of Gastroenterology (2019) 32, 1-6 Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation Dimitrios S. Politis a, Konstantinos

More information

Inflammatory bowel disease (IBD) patients have a higher risk of

Inflammatory bowel disease (IBD) patients have a higher risk of Serrated Colorectal Lesions in Patients With Inflammatory Bowel Disease Alyssa M. Parian, MD, and Mark G. Lazarev, MD Dr Parian and Dr Lazarev are assistant professors of medicine at Johns Hopkins University

More information

Pathology in Slovenian CRC screening programme:

Pathology in Slovenian CRC screening programme: Pathology in Slovenian CRC screening programme: Findings, organisation and quality assurance Snježana Frković Grazio University Medical Center Ljubljana, Slovenia Slovenia s population: 2 million Incidence

More information

Value of sigmoidoscopy and biopsy in detection of

Value of sigmoidoscopy and biopsy in detection of Gut, 1979, 20, 575-580 Value of sigmoidoscopy and biopsy in detection of carcinoma and premalignant change in ulcerative colitis R. H. RIDDELL' AND B. C. MORSON From the Department ofpathology, St. Marks

More information

Patients with inflammatory bowel disease (IBD) carry a higher

Patients with inflammatory bowel disease (IBD) carry a higher Advances in the Diagnosis and Management of Colonic Dysplasia in Patients With Inflammatory Bowel Disease Shirley Cohen-Mekelburg, MD, Yecheskel Schneider, MD, Stephanie Gold, MD, Ellen Scherl, MD, and

More information

Conflict of Interest. Inflammatory Bowel Disease. Road Map. Scope of the Disorder (United States) Age-Specific Incidence of IBD*

Conflict of Interest. Inflammatory Bowel Disease. Road Map. Scope of the Disorder (United States) Age-Specific Incidence of IBD* Inflammatory Bowel Disease Conflict of Interest No conflicts of interest Sonia Friedman, M.D. Assistant Professor of Medicine Gastroenterology Division Brigham and Women s Hospital Road Map Background

More information

Treatment Guidelines and Clinical Practice: Optimizing Foundational Therapies for Ulcerative Colitis

Treatment Guidelines and Clinical Practice: Optimizing Foundational Therapies for Ulcerative Colitis O c t o b e r 2 0 0 8 w w w. c l i n i c a l a d v a n c e s. c o m V o l u m e 4, I s s u e 1 0, S u p p l e m e n t 2 2 Faculty Stephen B. Hanauer, MD Program Chair Professor of Medicine and Clinical

More information

Large Colorectal Adenomas An Approach to Pathologic Evaluation

Large Colorectal Adenomas An Approach to Pathologic Evaluation Anatomic Pathology / LARGE COLORECTAL ADENOMAS AND PATHOLOGIC EVALUATION Large Colorectal Adenomas An Approach to Pathologic Evaluation Elizabeth D. Euscher, MD, 1 Theodore H. Niemann, MD, 1 Joel G. Lucas,

More information

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I

More information

ASGE and AGA Issue Consensus Statement on Surveillance and Management of Dysplasia in Patients With Inflammatory Bowel Disease

ASGE and AGA Issue Consensus Statement on Surveillance and Management of Dysplasia in Patients With Inflammatory Bowel Disease ASGE and AGA Issue Consensus Statement on Surveillance and Management of Dysplasia in Patients With Inflammatory Bowel Disease DOWNERS GROVE, Ill., (March 5, 2015) The American Society for Gastrointestinal

More information

5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA

5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA 5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA Background RCTs investigating the efficacy of aminosalicylates for

More information

SURGICAL MANAGEMENT OF ULCERATIVE COLITIS

SURGICAL MANAGEMENT OF ULCERATIVE COLITIS SURGICAL MANAGEMENT OF ULCERATIVE COLITIS Cary B. Aarons, MD Associate Professor of Surgery Division of Colon & Rectal Surgery University of Pennsylvania AGENDA Background Diagnosis/Work-up Medical Management

More information

RE: Title: Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis

RE: Title: Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis September 10, 2018 Professor Xue-Jiao Wang, MD Science Editor Editorial Office 'World Journal of Gastroenterology' RE: 40814 Title: Practical fecal calprotectin cut-off value for Japanese patients with

More information